Low 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2) among elderly: awareness warranted for 2017/18 season

Marc Rondy, Alin Gherasim, Itziar Casado, Odile Launay, Caterina Rizzo, Daniela Pitigoi, Aukse Mickiene, Sierk D Marbus, Ausenda Machado, Ritva K Syrjänen, Iva Pem-Novose, Judith Krisztina Horváth, Amparo Larrauri, Jesús Castilla, Philippe Vanhems, Valeria Alfonsi, Alina E Ivanciuc, Monika Kuliese, Rianne van Gageldonk-Lafeber, Veronica GomezNiina Ikonen, Zvjezdana Lovric, Annamária Ferenczi, Alain Moren, Giedre Gefenaite (medarbetare), I-MOVE+ hospital working group

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskriftPeer review

Sammanfattning

In a multicentre European hospital study we measured influenza vaccine effectiveness (IVE) against A(H3N2) in 2016/17. Adjusted IVE was 17% (95% confidence interval (CI): 1 to 31) overall; 25% (95% CI: 2 to 43) among 65-79-year-olds and 13% (95% CI: -15 to 30) among those ≥ 80 years. As the A(H3N2) vaccine component has not changed for 2017/18, physicians and public health experts should be aware that IVE could be low where A(H3N2) viruses predominate.

Originalspråkengelska
TidskriftEurosurveillance
Volym22
Nummer41
DOI
StatusPublished - 2017 okt.

Ämnesklassifikation (UKÄ)

  • Infektionsmedicin

Fingeravtryck

Utforska forskningsämnen för ”Low 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2) among elderly: awareness warranted for 2017/18 season”. Tillsammans bildar de ett unikt fingeravtryck.

Citera det här